Survey

With healthcare reform creating an FDA approval pathway for 'biosimilar' agents in the United States, what do you see as the primary implications of this from a managed care perspective in the next 3 years?

1) No impact, as I don't see any changes occurring soon

2) Limited savings with only a small number of products and small number of manufacturers

3) Moderate savings with the introduction of several products at moderate discounting to innovator brands

4) Significant savings with several biosimilar options, significant discounts and enhanced rebating from innovator brands

Digital Edition

ACIP revises guidelines for influenza vaccination

Confirm your e-newsletter subscription click here.

To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff

Analgesic medication errors, including prescribing errors, common but preventable

Medication errors involving analgesics, including mistakes in prescribing, are a major contributor to suboptimal therapeutic outcomes and preventable adverse patient events, according to a study
published in the Journal of Pain, reported Newswise.com. Read full article.

THERAPY UPDATE

A review of peripherally acting mu-opioid receptor antagonists

This article reviews the emerging class of peripherally acting mu-opioid receptor antagonists and provides insight on formulary considerations when evaluating these agents. Read full article.

FDA approves gabapentin once-daily for post-herpetic neuralgia

FDA has approved gabapentin (Gralise, Depomed and Abbott Products) tablets for once-daily treatment of
post-herpetic neuralgia. Read full article.

Fluzone linked with increase in febrile seizures in young children

An increase in febrile seizures in children following vaccination with Fluzone warrants further investigation, according to a report from FDA. Read full article.

Escitalopram reduces number and severity of menopausal hot flashes

Escitalopram, a selective serotonin reuptake inhibitor,
at doses of 10 or 20 mg/d significantly reduced hot
flash frequency and severity compared with placebo, according to a recent multicenter, double-blind study. Read full article.